Dallmann's Pharma GmbH (an indirect wholly-owned subsidiary of Katjes International GmbH & Co. KG) today signed an agreement to acquire the Bübchen business from Galderma Holding SA ("Galderma"). With this acquisition, Dallmann's Pharma acquires the market leader in the kids care segment in Germany.
Galderma (formerly Nestlé Skin Health) was acquired from Nestlé in October 2019 by a private equity consortium led by EQT and is selling the Bübchen business as part of the strategic positioning of its portfolio. Bübchen generated sales of approximately EUR 50 million in the last fiscal year and is profitable. Production takes place at a plant in Soest, Germany, with approximately 100 employees.
Dallmann's and Bübchen have a very high level of congruence in terms of their customers and sales, especially in drugstores.
"We are delighted to acquire Bübchen, an iconic brand in the kids' care segment. We expect to realize synergies by combining it with Dallmann's, with a largely identical customer base," says Tobias Bachmüller, Managing Partner of Katjes International. "Our model is the long-standing success of the Ricola and Klosterfrau combination in this area."
Completion of the transaction is expected very soon and is not subject to any conditions precedent. The acquisition will be financed through an acquisition loan from UniCredit and from current cash flow.
Katjes International was supported by WMCF as financial advisor in the transaction.